Loading
A phase 3 trial of Modified FOLFIRINOX Regimen in pancreatic ductal adenocarcinoma, run by Angiodynamics, Inc., active and no longer recruiting.
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer is a phase 3 interventional study registered as NCT03899636 by Angiodynamics, Inc., with 528 participants enrolled, started 2021-02-23 and due to reach its primary completion in 2025-04. Interventions recorded: Modified FOLFIRINOX Regimen and NanoKnife System.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/